Weiwei Yang1, Qinghua Li2, Jeremy W Duncan3, Bhavisha A Bakrania3, Jessica L Bradshaw3, Joey P Granger3, Sarosh Rana4, Frank T Spradley5. 1. School of Biosciences, Weifang Medical University, Weifang 261053, China; Department of Physiology and Biophysics, The University of Mississippi Medical Center, Jackson, MS 39216, United States. 2. School of Public Health and Management, Weifang Medical University, Weifang 261053, China; Department of Physiology and Biophysics, The University of Mississippi Medical Center, Jackson, MS 39216, United States. 3. Department of Physiology and Biophysics, The University of Mississippi Medical Center, Jackson, MS 39216, United States. 4. Department of Obstetrics and Gynecology, The University of Chicago, Chicago, IL 60637, United States. Electronic address: srana@bsd.uchicago.edu. 5. Department of Physiology and Biophysics, The University of Mississippi Medical Center, Jackson, MS 39216, United States; Department of Surgery, The University of Mississippi Medical Center, Jackson, MS 39216, United States.
Abstract
BACKGROUND: The flavonoid, luteolin, promotes vasorelaxation in various arteries through endothelial-dependent and independent mechanisms. Although there is growing interest in the vasoactive effects of flavonoids on maternal vascular function during pregnancy, it is unknown whether luteolin elicits vasorelaxation in the uterine circulation. We tested the hypothesis that luteolin induces vasorelaxation via endothelial-dependent mechanisms in uterine arteries from normal pregnant rats during late gestation. METHODS: Uterine arteries and aortas were isolated from Sprague-Dawley rats at gestational day 19 and prepared for wire myography. RESULTS: The potency of luteolin-induced vasorelaxation was examined between uterine arteries and the aortas. By 50 µM of luteolin, there was complete relaxation (100.5 ± 5.2%) in uterine arteries as compared to aortas (27.5 ± 10.0%). Even the highest concentration of 100 µM luteolin produced less than half relaxation (43.6 ± 8.6%) in aortas compared to uterine arteries. We then explored if luteolin-induced vasorelaxation in uterine arteries from pregnant rats was mediated by endothelial-dependent vasorelaxation pathways, including nitric oxide synthase (NOS), cyclooxygenase (COX), or potassium (K+) channels. Blocking these pathways with N(G)-Nitro-l-arginine methyl ester hydrochloride (L-NAME), indomethacin, or tetraethylammonium (TEA)/high potassium chloride (KCl), respectively, did not alter luteolin responses in uterine arteries from pregnant rats. These findings suggested that endothelial factors may not mediate luteolin-induced vasorelaxation in uterine arteries during pregnancy. Indeed, experiments where the endothelium was removed did not alter luteolin-induced vasorelaxation in uterine arteries during pregnancy. CONCLUSIONS: Luteolin directly promotes vasorelaxation in the medial smooth muscle layer of uterine arteries during normal pregnancy.
BACKGROUND: The flavonoid, luteolin, promotes vasorelaxation in various arteries through endothelial-dependent and independent mechanisms. Although there is growing interest in the vasoactive effects of flavonoids on maternal vascular function during pregnancy, it is unknown whether luteolin elicits vasorelaxation in the uterine circulation. We tested the hypothesis that luteolin induces vasorelaxation via endothelial-dependent mechanisms in uterine arteries from normal pregnant rats during late gestation. METHODS: Uterine arteries and aortas were isolated from Sprague-Dawley rats at gestational day 19 and prepared for wire myography. RESULTS: The potency of luteolin-induced vasorelaxation was examined between uterine arteries and the aortas. By 50 µM of luteolin, there was complete relaxation (100.5 ± 5.2%) in uterine arteries as compared to aortas (27.5 ± 10.0%). Even the highest concentration of 100 µM luteolin produced less than half relaxation (43.6 ± 8.6%) in aortas compared to uterine arteries. We then explored if luteolin-induced vasorelaxation in uterine arteries from pregnant rats was mediated by endothelial-dependent vasorelaxation pathways, including nitric oxide synthase (NOS), cyclooxygenase (COX), or potassium (K+) channels. Blocking these pathways with N(G)-Nitro-l-arginine methyl ester hydrochloride (L-NAME), indomethacin, or tetraethylammonium (TEA)/high potassium chloride (KCl), respectively, did not alter luteolin responses in uterine arteries from pregnant rats. These findings suggested that endothelial factors may not mediate luteolin-induced vasorelaxation in uterine arteries during pregnancy. Indeed, experiments where the endothelium was removed did not alter luteolin-induced vasorelaxation in uterine arteries during pregnancy. CONCLUSIONS: Luteolin directly promotes vasorelaxation in the medial smooth muscle layer of uterine arteries during normal pregnancy.
Authors: John J Reho; Jonathan D Toot; Jennifer Peck; Jacqueline Novak; Yang H Yun; Rolando J Ramirez Journal: Pregnancy Hypertens Date: 2011-12-13 Impact factor: 2.899
Authors: Vaughn A Browne; Colleen G Julian; Lillian Toledo-Jaldin; Darleen Cioffi-Ragan; Enrique Vargas; Lorna G Moore Journal: Philos Trans R Soc Lond B Biol Sci Date: 2015-03-05 Impact factor: 6.237
Authors: A L David; B Torondel; I Zachary; V Wigley; K Abi-Nader; K A Nader; V Mehta; S M K Buckley; T Cook; M Boyd; C H Rodeck; J Martin; D M Peebles Journal: Gene Ther Date: 2008-06-19 Impact factor: 5.250
Authors: Jasmine Tay; Giulia Masini; Carmel M McEniery; Dino A Giussani; Caroline J Shaw; Ian B Wilkinson; Phillip R Bennett; Christoph C Lees Journal: Am J Obstet Gynecol Date: 2018-09-19 Impact factor: 8.661
Authors: Laurent Chatre; Aurélien Ducat; Frank T Spradley; Ana C Palei; Christiane Chéreau; Betty Couderc; Kamryn C Thomas; Anna R Wilson; Lorena M Amaral; Irène Gaillard; Céline Méhats; Isabelle Lagoutte; Sébastien Jacques; Francisco Miralles; Frédéric Batteux; Joey P Granger; Miria Ricchetti; Daniel Vaiman Journal: Redox Biol Date: 2022-07-30 Impact factor: 10.787